Case LawActs & SectionsOpen the app
IP Intelligence

IP Case LawPatentsFMC Corporation & Ors. v. Natco Pharma Limited

Patents Ragulika IP case note

FMC Corporation & Ors. v. Natco Pharma Limited

CourtDelhi High Court
BenchHon'ble Justice Mini Pushkarna
Case numberCS(COMM) 607/2024 and I.A. 34151/2024
CitationCS(COMM) 607/2024
Judgment date17 November 2025
IP categoryPatents
PartiesFMC Corporation & Ors. (Plaintiffs) v. Natco Pharma Limited (Defendant)

Relevant Acts and provisions

Patents Act, 1970

Section 108Section 48Section 64(1)(a)Section 64(1)(e)

Provisions considered: Sections 48, 64(1)(a), 64(1)(e) and 108 of the Patents Act, 1970.

Brief facts

FMC Corporation and its group companies, co-patentees of an Indian patent for a process of preparing an insecticide, filed a quia timet suit against Natco Pharma to restrain use of a claimed intermediate compound in Natco's product. Natco, which had filed a revocation petition against the relevant claim, admitted using the intermediate but pleaded that the claim was invalid as anticipated by prior claiming and prior publication through a related patent and its international counterpart.

Issues before the Court

  1. Did the defendant's admitted manufacture and use of the intermediate establish a prima facie case of infringement under Section 48?
  2. Was the claim liable to be revoked as anticipated by prior claiming or prior publication?
  3. Did the pending revocation petition amount to a credible challenge sufficient to defeat interim relief?

Court's findings

The Court examined the rival cases on anticipation in detail, including the parties' competing readings of the earlier patent and its international counterpart against the asserted claim, and the significance of statements made by the plaintiffs during prosecution of the earlier patent. It noted that the defendant had raised substantial questions on prior claiming and prior publication that could not be dismissed as unsubstantial at the interim stage.

The Court held that, with the suit patent due to expire within about two weeks of the hearing and the defendant having already commenced commercial manufacture with significant investment, any injury to the plaintiffs pending trial would be compensable in damages.

The Court held that restraining an ongoing commercial operation at this late stage would cause disproportionate harm to the defendant, and that the balance of convenience accordingly favoured the defendant.

Decision

Application for interim injunction dismissed; the balance of convenience was held to favour the defendant.

Key legal principle / ratio

In a quia timet action under Sections 48 and 108 concerning a soon-to-expire patent, where the defendant has raised a substantial, non-frivolous challenge to validity through a pending revocation petition and has already commenced commercial manufacture, the balance of convenience may favour declining an interim injunction and leaving the patentee to a remedy in damages, notwithstanding admitted use of the claimed subject matter.

Keywords

Interim Injunction Novelty Patent Infringement Prior Art Revocation

Read the judgment

View judgment (court website)